Sponsored

Higher compliance & better patient outcomes? See how.

Finding the right patient services model isn’t a simple task. Traditionally, rare disease manufacturers have been served by multi-channel models made up of disparate service providers, each claiming expertise in their specific capabilities. The result…a rise in costs and a fall in outcomes as shown by average patient adherence data ranging between 58 to 65 percent. But this doesn’t have to be the case, and many companies are shifting their focus to more integrated models that drive better patient outcomes and financial results.

Access a new infographic from Dohmen Life Science Services here. Learn how an integrated and exclusive model with unique wrap-around services helps reduce unnecessary costs and helps manufacturers maintain control of your economics, inventory, brand, program and patients.

Get your free download here
 

............................................................................................................................................................................................................................................................................

Dohmen Life Science Services is the leading business process outsourcing partner to pharmaceutical and biologics companies. With the broadest suite of services in the industry, DLSS has helped more than 600 companies strengthen and simplify relationships with their customers, grow their business and realize their vision. Whether it’s navigating regulatory requirements during clinical trial, launching new products, managing daily operations or providing patient-centric care in support of products for rare diseases, DLSS helps our clients advance with speed, scale and certainty. A member of the Dohmen family of companies, visit www.dlss.com to learn more.

This article was created in collaboration with the sponsoring company and our sales and marketing team. The editorial team does not contribute.